Table 1.
Counts of Fos-positive cells from coronal brain sections
|
Region |
Reference (Fig. 1) |
CONTROL-SAL (n = 6) |
CONTROL-MDZ (n = 4) |
CAT-SAL (n = 7) |
CAT-MDZ (n = 6) |
||
|---|---|---|---|---|---|---|---|
| Sites at which midazolam reduces cat odor-induced c-fos expression | |||||||
| AON (lateral) | 2 | 16 (6.8) | 2 (2) | 31 (7.9)b,c | 10.5 (2.5) | ||
| AON (medial) | 5 | 18.2 (4.2) | 9 (3.5) | 35.4 (5.2)a,b,c | 12 (2.2) | ||
| AON (ventral) | 6 | 21 (7.3)b,c | 2.3 (0.8) | 37.9 (5.0)a,b,c | 5.2 (1.0) | ||
| MPC (prelimbic) | 7 | 18 (3.9) | 13 (5.0) | 60.7 (7.1)a,b,c | 18.5 (0.9) | ||
| Lateral septum (ventral) | 8 | 15 (3.14) | 6 (2.7) | 100.7 (9.8)a,b,c | 19.5 (3.7) | ||
| BNST (medial anterior) | 9 | 7.8 (1.8) | 2.7 (0.9) | 17.1 (1.8)a,b,c | 7.7 (1.0) | ||
| Medial preoptica area | 11 | 6.5 (1.8) | 4.7 (1.6) | 17 (3.1)a,b,c | 6 (1.6) | ||
| Lateral preoptic area | 12 | 4.7 (1.7) | 2.3 (0.5) | 24.7 (3.5)a,b,c | 5.7 (2.0) | ||
| Anterior hypothalamic area (posterior) | 15 | 20 (4.1) | 12.8 (4.3) | 63.7 (6.5)a,b,c | 28 (6.1) | ||
| Dorsomedial hypothalamus | 20 | 12.2 (1.8) | 5.8 (2.2) | 34.2 (6.6)a,b,c | 18.7 (2.8) | ||
| MePV | 22 | 12 (4.2) | 6 (1.0) | 65.4 (6.2)a,b,c | 47.5 (7.3)a,b | ||
| PMd | 24 | 6 (1.6) | 1.8 (1.1) | 63.9 (9.9)a,b,c | 24.8 (9.3)a,b | ||
| Sites at which midazolam does not significantly affect cat odor-induced c-fos expression | |||||||
| AOB (mitral layer) | 1 | 18.5 (2.6) | 17.3 (3.5) | 44.4 (6.5)a,b | 50.3 (3.6)a,b | ||
| PVN | 14 | 7.7 (1.4) | 15.5 (5.1) | 51.7 (14.4)a,b | 68.2 (14.7)a,b | ||
| BAOT (40X) | 16 | 5.8 (2.1) | 2.3 (1.0) | 17 (2.5)a,b | 12.5 (1.6)b | ||
| VMH (dorsomedial) (40X) | 21 | 3 (1.0) | 6.3 (6.3) | 36.9 (6.6)a,b | 28.5 (8.1)a,b | ||
| PAG (dorsomedial) | 26 | 5.7 (1.0) | 7.3 (1.7) | 30.9 (5.0)a,b | 25.8 (3.6)a,b | ||
| PAG (dorsolateral) | 27 | 7.2 (1.4) | 6.5 (2.3) | 35.9 (4.3)a,b | 31.3 (7.0)a,b | ||
| PAG (ventrolateral) | 29 | 5.2 (1.4) | 5.3 (1.4) | 38.3 (11.1)a,b | 29.2 (6.7)a,b | ||
| Cuneiform nucleus | 30 | 4.5 (1.9) | 11.7 (1.9) | 34.6 (6.7)a,b | 25 (4.6)a,b | ||
| Locus ceruleus | 32 | 0.7 (0.5) | 0.5 (0.9) | 8.9 (3.2)a,b | 15.7 (3.2)a,b | ||
| Sites at which midazolam increases c-fos expression | |||||||
| BNST (dorsolateral) (40X) | 10 | 5.2 (1.6) | 14.5 (3.5)a | 9.3 (2.5) | 36 (6.6)a,b,d | ||
| CEA | 18 | 4.2 (1.0) | 20.8 (4.0)a,d | 2.9 (1.2) | 32 (7.1)a,d | ||
| Edinger-Westphal nucleus (40X) | 28 | 3.17 (1.2) | 14.5 (5.1)a | 7 (1.7) | 21.7 (4.)a,d | ||
| Lateral parabrachial nucleus | 31 | 2.7 (1.0) | 7.8 (2.7)a | 3.9 (0.9) | 23.6 (5.2)a,b,d | ||
| Sites at which midazolam reduces basal c-fos expression | |||||||
| MOB (+5.7) (40X) | 3 | 36.7 (11.4)b,c | 7 (2.6) | 38.7 (7.7)b,c | 10.6 (1.6) | ||
| MOB (+5.2) (40X) | 4 | 25.7 (6.6)b,c | 6.3 (1.4) | 38.9 (5.5)b,c | 9.3 (1.8) | ||
| Sites that were mostly unaffected | |||||||
| Supraoptic nucleus (40X) | 13 | 2.2 (0.8) | 1.3 (0.9) | 5 (2.0) | 4.8 (1.6) | ||
| Anterior cortical amygdala (40X) | 17 | 12.2 (2.2) | 5.3 (2.0) | 16.3 (1.6) | 11.5 (1.9) | ||
| Basolateral amygdala | 19 | 5.7 (1.8) | 1.3 (1.0) | 11.6 (3.0)b | 6.8 (1.7) | ||
| Medial amygdala (posterodorsal) | 23 | 9.3 (1.9) | 3.5 (0.6) | 11.6 (3.2) | 5 (1.0) | ||
| Premammillary nucleus (ventral) |
25 |
12.5 (3.3) |
2.8 (1.5) |
8.6 (3.2) |
4.2 (1.2) |
||
Data are mean (SEM). All counts were made within graticule at 20X magnification, except when indicated in which 40X magnification was used (40X). PVN, Paraventricular nucleus; BAOT, bed nucleus of the accessory olfactory tract.
a p < 0.05 versus CONTROL-SAL group;b p < 0.05 versus CONTROL-MDZ group;c p < 0.05 versus CAT-MDZ group;d p < 0.05 versus CAT-SAL group.